Comparative Pharmacology
Head-to-head clinical analysis: DIMETHYL SULFOXIDE versus SALONPAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETHYL SULFOXIDE versus SALONPAS.
DIMETHYL SULFOXIDE vs SALONPAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimethyl sulfoxide (DMSO) is a polar aprotic solvent that penetrates biological membranes, scavenges hydroxyl radicals, and stabilizes lysosomal membranes. It has anti-inflammatory, analgesic, and cryoprotective properties. It enhances cutaneous absorption of other drugs and induces histamine release from mast cells, causing vasodilation and urticaria.
Salicylate topical analgesic; inhibits cyclooxygenase (COX) and prostaglandin synthesis, providing local anti-inflammatory and analgesic effects.
50% solution topically applied every 6 hours; intravenous: 0.5-1 g/kg as a 10-20% solution over 30-60 minutes every 6 hours for 3-5 doses
Apply one 10 cm x 14 cm patch topically to affected area every 12 hours; maximum 2 patches daily.
None Documented
None Documented
Clinical Note
moderateDimethyl sulfoxide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide."
Clinical Note
moderateDimethyl sulfoxide + Atorvastatin
"The risk or severity of adverse effects can be increased when Dimethyl sulfoxide is combined with Atorvastatin."
Clinical Note
moderateDimethyl sulfoxide + Dexrazoxane
"The therapeutic efficacy of Dexrazoxane can be decreased when used in combination with Dimethyl sulfoxide."
Clinical Note
moderateTerminal half-life: 11-14 hours for DMSO; DMSO2 half-life 60-70 hours, accumulates with repeated dosing. Clinical context: renal impairment prolongs half-life.
Approximately 2-3 hours for salicylate at therapeutic concentrations; increases dose-dependently (e.g., >20 hours at anti-inflammatory doses) due to saturation of hepatic metabolism. Clinical context: extended half-life at high doses requires monitoring for accumulation.
Renal: 30-50% unchanged; hepatic metabolism to dimethyl sulfone (DMSO2) and dimethyl sulfide (DMS); DMSO2 excreted renally, DMS exhaled; fecal elimination <5%.
Primarily renal excretion of glucuronide conjugates and unchanged drug; approximately 50-60% excreted in urine as glucuronide conjugates, 10-20% as unchanged salicylate, and <5% as salicyluric acid. Biliary excretion is minimal, with less than 5% eliminated in feces.
Category C
Category C
Topical Analgesic
Topical Analgesic
Metoprolol + Dimethyl sulfoxide
"The serum concentration of Dimethyl sulfoxide can be increased when it is combined with Metoprolol."